New dialysis system aims to improve kidney care

NCT ID NCT07216885

Recruiting now Disease control Sponsor: Mozarc Medical US LLC Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a new dialysis system called Solv Multi-Pass for people with end-stage kidney disease. The device is designed to remove waste and extra fluid from the blood during in-center dialysis sessions. Researchers will check how safe it is and how well it works in 46 adult patients over eight weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Solv Multi-Pass Hemodialysis System (device)
What this could lead to: If successful, this could provide a new, safe option for in-center hemodialysis, potentially improving treatment for kidney failure patients.
What could go wrong: This is an early-stage study with only 46 participants, so results may not apply to everyone. Device-related side effects or technical issues could occur.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END-STAGE RENAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

END-STAGE RENAL DISEASE

Contacts and locations

Locations

Carolina Nephrology
RECRUITING

Greenville, South Carolina, 29605, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.